(Q36715285)

15 August 2017

1 reference

title

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy (English)

1 reference

15 August 2017

0 references

1 reference

Qi Zhang

1

1 reference

15 August 2017

Guihua Chen

series ordinal

2

1 reference

15 August 2017

Xinyuan Liu

series ordinal

3

1 reference

15 August 2017

Qijun Qian

series ordinal

4

1 reference

15 August 2017

publication date

1 February 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

17

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

89-99

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Engineering antibodies for clinical applications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Pharmacokinetics and biodistribution of genetically engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Antibody-based therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Overview of monoclonal antibodies in cancer therapy: present and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Current methods for the generation of human antibodies for the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Recombinant antibodies for the diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Generation and production of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Therapeutic applications of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Development of humanized antibodies as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Monoclonal antibodies as therapeutic agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Immunochemotherapy in indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Panitumumab in colon cancer: a review and summary of ongoing trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Antibody conjugates and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Drug-conjugated monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Stable antibody expression at therapeutic levels using the 2A peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Adenoviral vectors: a promising tool for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Adenovirus: from foe to friend.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Adenoviral strategies for the gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

7 January 2021

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CR.7310143

7 January 2021

Identifiers

DOI

10.1038/SJ.CR.7310143

1 reference

Dimensions Publication ID

15 August 2017

1004807532

0 references

1 reference